{
    "id": 27199,
    "fullName": "CD70 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD70 positive indicates the presence of the CD70 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 970,
        "geneSymbol": "CD70",
        "terms": [
            "CD70",
            "CD27-L",
            "CD27L",
            "CD27LG",
            "LPFS3",
            "TNFSF7",
            "TNLG8A"
        ]
    },
    "variant": "positive",
    "createDate": "11/02/2017",
    "updateDate": "04/09/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16220,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CD70-positive patients with either diffuse large B-cell lymphoma or mantle cell lymphoma demonstrated an objective response rate of 20% (4/20) when treated with SGN-CD70A, including a complete response in one patient and a partial response in three patients, and six patients experienced stable disease (PMID: 30132271; NCT02216890).",
            "molecularProfile": {
                "id": 28616,
                "profileName": "CD70 positive"
            },
            "therapy": {
                "id": 7942,
                "therapyName": "SGN-CD70A",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14343,
                    "pubMedId": 30132271,
                    "title": "A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30132271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12271,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ARGX-110 demonstrated tolerability and some preliminary anti-tumor activity in patients with advanced solid tumors or hematological malignancies, with treatment resulting in stable disease as best response in 53.8% (14/26) patients (PMID: 28765328).",
            "molecularProfile": {
                "id": 28616,
                "profileName": "CD70 positive"
            },
            "therapy": {
                "id": 6400,
                "therapyName": "ARGX-110",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10230,
                    "pubMedId": 28765328,
                    "title": "Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765328"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28616,
            "profileName": "CD70 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}